Jun. 30, 2016
Monsanto Company and Nomad Bioscience GmbH have announced a licensing agreement whereby Monsanto has obtained rights to apply Nomad’s proprietary technology to its genome-editing projects aimed at enhancement of agricultural crops. The licensed technology enables more efficient development of edited traits and may be applied across a broad range of genome-editing technologies and project types. Nomad’s novel approach holds the promise to accelerate the development of improved agricultural products via genome editing.
“Our approach greatly increases both the efficiency of genome editing and the ability to deploy edited traits in commercial varieties, which could prove to be beneficial to the speed and scale at which potential products are developed,” said Dr. Yuri Gleba, chief executive officer and Nomad founder.
The agreement includes a three-year research project, during which scientists at Nomad will continue to expand the applicability of their technology. In addition, the agreement provides Monsanto with rights to use Nomad’s technology for research projects during the term, as well as an option for an exclusive commercial license to apply the proprietary technology in the development of agriculture products. Additional details of the agreement were not disclosed.
“Monsanto is committed to delivering best-in-class solutions to growers who face increasing challenges every year,” said Tom Adams, biotechnology lead for Monsanto. “Our collaboration with Nomad is one example of how we employ the industry’s best science through our own R&D pipeline and through strategic partnerships to continually drive agriculture innovation.”